Payment overview · 2025
General Payments
$422.70
22 reported records · 18 companies
Healthcare provider profile · identity verified
Kenyn L. Koop, MD
Allopathic & Osteopathic Physicians|Family Medicine · JANESVILLE, WI · NPI 1124507439
Verified facts
What the public records show
CMS Open Payments records show Kenyn L. Koop, MD received $422.70 in general payments during 2025 across 22 reported records.
Madrigal Pharmaceuticals accounted for 11.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $48.89 | 11.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $42.68 | 10.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $39.85 | 9.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.08 | 7.3% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $31.03 | 7.3% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $27.20 | 6.4% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $23.42 | 5.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.32 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $21.38 | 5.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $17.53 | 4.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.40 | 3.9% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $16.22 | 3.8% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $16.19 | 3.8% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.43 | 3.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.12 | 3.3% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$13.59 | 3.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.26 | 3.1% | 1 | 2025 |
| The Binding Site Inc. | Unresolved — no canonical attribution shown | $11.11 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $422.70 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $48.89 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.08 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $27.20 | 1 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.40 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.26 | 1 | 2025 |
Source payment records
|
|||||
| Freelite Normalized: freelite |
Device | The Binding Site Inc. | $11.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 619 | 215 |
| Omeprazole | Omeprazole | 376 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 347 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 319 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 275 | 95 |
| Losartan Potassium | Losartan Potassium | 263 | 92 |
| Lisinopril | Lisinopril | 257 | 95 |
| Simvastatin | Simvastatin | 257 | 80 |
| Trazodone Hcl | Trazodone Hcl | 257 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 244 | 87 |
| Metformin Hcl Er | Metformin Hcl | 239 | 58 |
| Gabapentin | Gabapentin | 232 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 214 | 66 |
| Potassium Chloride | Potassium Chloride | 209 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 69 |
| Doxazosin Mesylate | Doxazosin Mesylate | 156 | 41 |
| Enalapril Maleate | Enalapril Maleate | 147 | 30 |
| Metformin Hcl | Metformin Hcl | 140 | 47 |
| Furosemide | Furosemide | 137 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 49 |
| Clonidine Hcl | Clonidine Hcl | 130 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 124 | 32 |
| Montelukast Sodium | Montelukast Sodium | 123 | 34 |
| Prednisone | Prednisone | 121 | 69 |
| Meloxicam | Meloxicam | 115 | 45 |
| Celecoxib | Celecoxib | 112 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 109 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 26 |
| Alendronate Sodium | Alendronate Sodium | 99 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 98 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 97 | 43 |
| Famotidine | Famotidine | 95 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 28 |
| Eliquis | Apixaban | 86 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 36 |
| Allopurinol | Allopurinol | 84 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 84 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 35 |
| Carvedilol | Carvedilol | 81 | 28 |
| Ozempic | Semaglutide | 79 | 25 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 74 | 17 |
| Nifedipine Er | Nifedipine | 71 | 26 |
| Amitriptyline Hcl | Amitriptyline Hcl | 70 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 64 | 25 |
| Buspirone Hcl | Buspirone Hcl | 63 | 16 |
| Glipizide | Glipizide | 55 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | 20 |
| Jardiance | Empagliflozin | 53 | 19 |
| Spironolactone | Spironolactone | 53 | 14 |
| Donepezil Hcl | Donepezil Hcl | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 43 |
| Glimepiride | Glimepiride | 49 | 15 |
| Mounjaro | Tirzepatide | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | 19 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 47 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 12 |
| Memantine Hcl | Memantine Hcl | 46 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 15 |
| Clonazepam | Clonazepam | 44 | 11 |
| Mirtazapine | Mirtazapine | 44 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Alprazolam | Alprazolam | 42 | 12 |
| Synthroid | Levothyroxine Sodium | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 38 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 14 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 37 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 28 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 12 |
| Januvia | Sitagliptin Phosphate | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 12 |
| Sertraline Hcl | Sertraline Hcl | 30 | 15 |
| Finasteride | Finasteride | 29 | 13 |
| Lorazepam | Lorazepam | 28 | 13 |
| Ranolazine Er | Ranolazine | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | 12 |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fenofibrate | Fenofibrate | 25 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Telmisartan | Telmisartan | 23 | 11 |
| Topiramate | Topiramate | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Felodipine Er | Felodipine | 22 | suppressed |
| Klor-Con M20 | Potassium Chloride | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | 11 |
| Estradiol | Estradiol | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Clonidine | Clonidine | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $422.70 · 22 records | Madrigal Pharmaceuticals | AIRSUPRA, Dexcom G6 Transmitter, Exablate, Freelite, Gamunex-C, HADLIMA, Hizentra, INCEPTIV, INGREZZA, JATENZO, Leqembi, REZDIFFRA, Rystiggo, TZIELD, Tymlos, VOQUEZNA, VYEPTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error